期刊文献+

可溶性MICA在乳腺癌免疫逃逸中的作用 被引量:10

The roles of soluble MICA in immune escape of breast tumor
下载PDF
导出
摘要 目的:观察乳腺癌患者血清中可溶性MICA(sMI-CA)表达情况,探讨sMICA在乳腺癌免疫逃逸中的作用。方法:ELISA方法检测乳腺肿瘤患者外周血sMICA的分泌。流式细胞术(FCM)检测sMICA及白细胞介素15(IL-15)对NK细胞表面NKG2D表达的影响。MTT法检测NK细胞对乳腺癌细胞的杀伤活性。结果:ELISA结果显示,血清sMICA含量在健康成年人血清中为阴性,在乳腺良性肿瘤患者血清中含量为(76.8±22.3)ng/L,在恶性肿瘤患者血清中含量为(205.36±71.27)ng/L,乳腺癌患者中血清sMICA含量高低与TNM分期呈正相关。应用含sMICA的血清与NK细胞共培养可明显下调NK细胞的杀瘤活性[(76.2±6.7)%vs(48.4±4.1)%],NK细胞表面NKG2D表达和上清中IFN-γ分泌量也下降。IL-15明显上调NK细胞表面NKG2D表达,增加培养上清IFN-γ分泌量和增强NK对MCF-7的杀瘤活性。结论:sMICA表达与乳腺癌TNM分期正相关,sMICA通过下调NK细胞NKG2D表达水平而降低NK细胞杀瘤活性,在肿瘤免疫逃逸中起重要作用。IL-15可以上调NK细胞NKG2D的表达并增强NK细胞杀瘤活性。 AIM; To determine the expression of soluble MICA (sMICA) in serum of patients with breast tumor, and explore the roles of sMICA in immune escape. METHODS: ELISA was used to examine the sMICA in peripheral blood. The expression of NKG2D were identified by Flow cytometry. The cytotoxicity of NK cells to breast cancer cells was observed with MTT assay. RESULTS: sMICA was not detected in the serum of healthy person, but (76.8 ± 22.3 ) ng/L in breast benign tumor patients and(205.4 ±71.3)ng/L in breast malignant tumor patients. There was positive correlation between sMICA levels and breast cancer stage. After incubation with sMICA, NK cells got decrease in cytotoxicity from(76.2 ±6.7)% to (48.4±4. 1 )% . The expression of NKG2D and secretion of IFN-γ decreased at the same time. IL-15 up-regulated the expression of NKG2D on NK cells and increased NK cells cytotoxicity to breast cancer cells. CONCLUSION: sMICA level is positive correlated with breast cancer TNM stage, sMICA reduced the expression of NKG2D, impaired NK-mediated immune surveillance and led to immune escape of breast tumor. IL-15 could upregulate the expression of NKG2D and increase NK cells cytotoxicity.
出处 《细胞与分子免疫学杂志》 CAS CSCD 北大核心 2008年第9期904-907,共4页 Chinese Journal of Cellular and Molecular Immunology
关键词 自然杀伤细胞 乳腺肿瘤 MICA NK细胞受体 natural killer cell breast tumor MICA NK cell receptor
  • 相关文献

参考文献17

  • 1齐红,单征,于宏波.乳腺癌患者T淋巴细胞免疫功能及NK活性检测分析[J].中国实验诊断学,2007,11(1):51-52. 被引量:16
  • 2Varker KA, Terrell CE, Welt M. Impaired natural killer cell lysis in breast cancer patients with high levels of psychological stress is associated with altered expression of killer immunoglobin-like receptors[J]. J Surg Res, 2007,139(1):36-44.
  • 3Lanier LL. NK cell recognition[J]. Annu Rev Immunol, 2005,23(2):225-274.
  • 4Holdenrieder S, Stieber P, Peterfi A, et al. Soluble MICA in malignant diseases[J]. Int Cancer, 2006,118(3):684-687.
  • 5Rebmann V, Schutt P, Brandhorst D, et al. Soulble MICA as an independent prognostic factor for the overall survival and progression-free survival of multiple myeloma patients[J]. Clin Immonol, 2007,123(1):114-120.
  • 6尹凌凡,范艳莹,李丽,吴长有.Toll样配体(R-848)与IL-12对人NK细胞亚群IFN-γ产生的作用[J].细胞与分子免疫学杂志,2007,23(7):623-626. 被引量:9
  • 7Doubrovina ES, Doubrovin MM, Vider E, et al. Evasion from NK cell immunity by MHC class Ⅰ chain-related moleculer expressing colon adenocarcinomal[J]. J Immunol, 2003,171(12):6891-6899.
  • 8Diefenbach A, Jamieson AM, Liu SD, et al. Ligands for the murine NKG2D receptor: expression by tumor cells and activation of NK cells and macrophages[J]. Nat Immunol, 2000,1(2):119-126.
  • 9叶韵斌,周智锋,郑蕊蕊,陈强,林建银,李洁羽.KIR不相合的NK细胞对乳腺癌细胞的体外杀伤作用[J].中国肿瘤生物治疗杂志,2007,14(1):26-30. 被引量:6
  • 10Diefenbach A, Jensen ER, Jamieson AM, et al. Rae 1 and H60 ligands of the NKG2D receptor stimulate tumour immunity[J]. Nature, 2001,413(6852):165-171.

二级参考文献46

  • 1吴长有,刘杰,杨滨燕,Mario Roedere.人外周血NK细胞亚群、表型和生物学特征[J].中国免疫学杂志,2005,21(7):483-486. 被引量:34
  • 2范艳莹,吴长有.Th2细胞因子和抗IL-12Rβ1mAb抑制由IL-23诱导PBMCIFN-γ的产生[J].中国免疫学杂志,2006,22(3):195-199. 被引量:9
  • 3吴长有,刘杰,杨滨燕,Mario Roedere.人外周血CD56^+NK细胞亚群表型和生物学特征[J].中华肿瘤杂志,2006,28(3):169-172. 被引量:12
  • 4徐元斌 王德春 等.恶性肿瘤特异性生长因子(TSGF)测定及临床应用[J].福建医学检验,1996,1(3):118-118.
  • 5孙玉萍 申红 等.血清肿瘤标志物CA153在乳腺癌治疗中的应用[J].标记免疫分析与临床,1998,5(2):105-106.
  • 6孙龙安 李龙 林钢 等.医学特种检验与实验室诊断[M].北京:人民军医出版社,2001.159.
  • 7Och Y, Okabe H, Inui J, et al. Tumor marker-present and future. Rinsho Bvori, 1997, 45(9): 875-883.
  • 8Gion M, Mione R, Leon AE, et al. Comparison of the diagnostic accuracy of CA27.29 and CA15-3 in primary breast cancer. Clin Chem, 1999,45(5) :630-637.
  • 9Cioffi M, Fratta M, Delucia D. CEA, TPA and CA15-3 in breast cancer. Cancer Detect Prevent, 1993,17 ( 1 ) : 87-89.
  • 10Molina R,Judith J,Xavier F,et al.C-erbB-2 oncoprotein,CEA and CA153 in patients with breast cancer:prognostic value[J].Breast Cancer Res Treat,1998,51 (3):109-119.

共引文献66

同被引文献61

引证文献10

二级引证文献17

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部